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Abstract: Inherited retinal diseases (IRDs) display an enormous genetic heterogeneity. Whole
exome sequencing (WES) recently identified genes that were mutated in a small proportion of
IRD cases. Consequently, finding a second case or family carrying pathogenic variants in the
same candidate gene often is challenging. In this study, we searched for novel candidate IRD
gene-associated variants in isolated IRD families, assessed their causality, and searched for novel
genotype-phenotype correlations. Whole exome sequencing was performed in 11 probands affected
with IRDs. Homozygosity mapping data was available for five cases. Variants with minor allele
frequencies ≤ 0.5% in public databases were selected as candidate disease-causing variants. These
variants were ranked based on their: (a) presence in a gene that was previously implicated in IRD;
(b) minor allele frequency in the Exome Aggregation Consortium database (ExAC); (c) in silico
pathogenicity assessment using the combined annotation dependent depletion (CADD) score;
and (d) interaction of the corresponding protein with known IRD-associated proteins. Twelve
unique variants were found in 11 different genes in 11 IRD probands. Novel autosomal recessive
and dominant inheritance patterns were found for variants in Small Nuclear Ribonucleoprotein U5
Subunit 200 (SNRNP200) and Zinc Finger Protein 513 (ZNF513), respectively. Using our pathogenicity
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assessment, a variant in DEAH-Box Helicase 32 (DHX32) was the top ranked novel candidate
gene to be associated with IRDs, followed by eight medium and lower ranked candidate genes.
The identification of candidate disease-associated sequence variants in 11 single families underscores
the notion that the previously identified IRD-associated genes collectively carry > 90% of the defects
implicated in IRDs. To identify multiple patients or families with variants in the same gene and
thereby provide extra proof for pathogenicity, worldwide data sharing is needed.
Keywords: whole exome sequencing; inherited retinal diseases; candidate retinal disease genes
1. Introduction
Inherited retinal diseases (IRDs) comprise of a clinically and genetically heterogeneous group
of hereditary retinal degenerations, which affect around 1 in 3000 people. Inherited Retinal Diseases
may occur both in syndromic and non-syndromic forms, and can be inherited in all the Mendelian
inheritance patterns. Inherited Retinal Diseases are one of the leading causes of vision loss in young
individuals in the developed countries, with a significant impact on patients and society [1–3]. In the
past two decades, new therapies have been developed that rely on knowledge of the underlying
genetic defects [4–6].
The high genetic diversity and overlapping phenotypes of IRDs pose significant challenges in
the genetic elucidation of these disorders. The spectrum of genotyping technologies employed in
the last three decades, ranging from positional cloning, (mouse) candidate disease gene analyses,
linkage analysis, homozygosity mapping, and whole exome sequencing (WES) have led to a wide
body of knowledge regarding the molecular genetics of IRDs. Currently, mutations in 261 genes have
been discovered to be involved in IRDs [7]. Nevertheless, there is a trend in which the more recently
discovered IRD-associated genes are responsible for a very small percentage of cases, in comparison
to the genes that were discovered in the earlier studies. Two WES studies in the Saudi-Arabian and
the Dutch population showed that only ~3–4% of IRD cases carry variants in novel IRD-associated
genes [8–12]. Consequently, finding additional cases carrying variant(s) in the same candidate gene is
often challenging.
A large cohort of IRD cases is crucial to assess the contribution of unique variants in causing
diseases. The European Retinal Diseases Consortium (ERDC) [13], consisting of 17 research groups,
was formed as a collaborative effort to elucidate molecular genetics causes of IRDs. Within the ERDC,
information on candidate IRD genes was shared which enabled the identification of multiple cases or
families with variants in the same gene [14–17].
In this study, we report on the identification of potential candidate disease variants in 11 genes that
were found in single families. We assessed the causality of these candidate disease variants, searched
for novel genotype-phenotype correlations and investigated the occurrence of different inheritance
patterns for variants in known IRD-associated genes.
2. Materials and Methods
2.1. Subject and Clinical Evaluation
The study protocol adhered to the tenets of the declaration of Helsinki and received approval
from the respective local ethics committees (2011, MEC-2010-359, ABR-NL34152.078.10; 2004, 03/362
17/YH/0365; 2015, 176953, 15/YH/0365; 2008-A01238-47). Written informed consent was obtained
from all participants or parents of children prior to their inclusion in this study. The 11 probands
belong to eight autosomal recessive retinitis pigmentosa (RP) families, two autosomal dominant RP
families, one autosomal recessive cone-rod dystrophy (CRD) family, one achromatopsia (Figures 1 and 2,
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Tables 1 and 2). Each patient was reviewed for clinical examination including visual acuity, fundus
photography, fundus autofluorescent, and optical coherence tomography.Genes 2018, 9, 21  3 of 16 
 
 
Figure 1. Pedigrees of families (Fam) harboring inherited retinal diseases (IRD) candidate gene 
variants inherited in an autosomal recessive manner. Double lines denote consanguinity, open 
squares and circles represent healthy males and females respectively, black squares and circles 
represent affected males and females respectively, diagonal line indicates deceased person, arrows 
point to the probands, Roman numbers denote the generation number, Greek numbers address the 
individual in each generation, V1 and V2 depicts the variants in the families, Y denotes Y-
chromosome, ‘+’ indicates a wild type allele, (;) indicates that segregation analysis was not performed. 
DHX32: DEAH-Box Helicase 32; DSCAML1: DS Cell Adhesion Molecule Like 1; FDFT1: Farnesyl-
Diphosphate Farnesyltransferase 1; GPR45: G Protein-Coupled Receptor 45; NDRG4: NDRG Family 
Member 4; OTOGL: Otogelin Like; SNRNP200: Small Nuclear Ribonucleoprotein U5 Subunit 200; 
SYTL4: Synaptotagmin Like 4; TMED7: Transmembrane P24 Trafficking Protein 7.  
Figure 1. Pedigrees of families (Fam) harboring inherited retinal diseases (IRD) candidate gene
variants inherited in an autosomal recessive manner. Double lines denote consanguinity, open squares
and circles represent healthy males and females respectively, black squares and circles represent
affected males and females respectively, diagonal line indicates deceased person, arrows point to the
probands, Roman numbers denote the generation number, Greek numbers address the individual in
each generation, V1 and V2 depicts the variants in the families, Y denotes Y-chromosome, ‘+’ indicates a
wild type allele, (;) indicates that segregation analysis was not performed. DHX32: DEAH-Box Helicase
32; DSCAML1: DS Cell Adhesion Molecule Like 1; FDFT1: Farnesyl-Diphosphate Farnesyltransferase
1; GPR45: G Protein-Coupled Receptor 45; NDRG4: NDRG Family Member 4; OTO L: Otogelin Like;
SNRNP200: Small Nuclear Ribonucleoprotein U5 ubunit 200; SYTL4: Synaptotagmin Like 4; TMED7:
Transmembrane P24 Trafficking Protein 7.
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Figure 2. Pedigrees of families harboring IRD candidate gene variants inherited in an autosomal 
dominant manner. Open squares and circles represent healthy males and females, black squares and 
circles represent affected males and females, and diagonal line indicates deceased person, arrows 
point to the probands. The question mark depicts a person who deceased too young to possibly 
develop the disease. The vertical line represents a person affected by hearsay. Asterisks (*) denote 
non-penetrant persons. Roman numbers denote the generation number, Greek numbers address the 
individual within in the generation, V1 depicts the variant in the families, ‘+’ indicates a wild-type 
allele. EP300: E1A Binding Protein P300; ZNF513: Zinc Finger Protein 513. 
2.2. Genetic Analysis 
Genomic DNA was isolated from peripheral blood lymphocytes according to standard salting 
out procedures. Whole exome sequencing analysis consisting of targeted capture, sequencing 
platform, and mapping was independently performed by each center using several types of software 
(Supplementary Table S1) [18–20]. Sequences were aligned to National Center for Biotechnology 
Information (NCBI) Build 37 of the human genome [21] using corresponding mapping tools and copy 
number variant analyses were performed. Single nucleotide polymorphism (SNP) microarray 
analysis was performed in five families and the runs of homozygosity were assessed using PLINK or 
Homozygosity mapper [20,22]. 
2.3. Variant Prioritization 
Whole exome sequencing identified approximately 120,000 variants in each proband. Inclusion 
of rare variants with minor allele frequency (MAF) ≤ 0.5% was performed as an initial filtering step. 
Thereafter, protein coding and splice site variants were filtered and assessed using in silico prediction 
tools to prioritize the remaining variants. Four parameters were used to assess the pathogenicity of 
candidate variants: (a) minor allele frequencies obtained from the Exome Aggregation Consortium 
(ExAC) [23] database containing 60,706 exomes of unrelated healthy individuals, accessed September 
2017, (b) in silico pathogenicity assessment using the combined annotation dependent depletion 
(CADD) score, (c) interaction with known IRD-associated proteins, and (d) known association of the 
relevant gene with IRDs. Using these criteria, all of the candidate genes were scored and ranked 
according to the number of matching parameters. The total score corresponded to the likelihood of a 
gene to be associated with IRDs. Yet Another Scientific Artificial Reality Application (Yasara) [24] 
was used to model the possible three-dimensional (3D) structural alterations caused by Small Nuclear 
Ribonucleoprotein U5 Subunit 200 (SNRNP200) amino acid changes [25]. Primers for candidate 
variants confirmation were designed with Primer3 plus [26].  
2.4. Data Sharing 
Each ERDC partner shared candidate genes in biannual meetings. Thereafter, the corresponding 
genes were screened for the presence of variants in WES data and homozygosity mapping data were 
assessed for homozygous regions larger than 4 Mb containing these candidate genes. In addition, 
Figure 2. Pedigrees of families harboring IRD candidate gene variants inherited in an autosomal
dominant manner. Open squares and circles represent healthy males and females, black squares and
circles represent affected males and females, and diagonal line indicates deceased person, arrows point
to the probands. The question mark depicts a person who deceased too young to possibly develop the
disease. The vertical line represents a person affected by hearsay. Asterisks (*) denote non-penetrant
persons. Roman numbers denote the generation number, Greek numbers address the individual within
in the generation, V1 depicts the variant in the families, ‘+’ indicates a wild-type allele. EP300: E1A
Binding Protein P300; ZNF513: Zinc Finger Protein 513.
2.2. Genetic Analysis
Genomic DNA was isolated from peripheral blood lymphocytes according to standard salting
out procedures. Whole exome sequencing analysis consisting of targeted capture, sequencing
platform, and mapping was independently performed by each center using several types of software
(Supplementary Table S1) [18–20]. Sequences were aligned to National Center for Biotechnology
Information (NCBI) Build 37 of the human genome [21] using corresponding mapping tools and
copy number variant analyses were performed. Single nucleotide polymorphism (SNP) microarray
analysis was performed in five families and the runs of homozygosity were assessed using PLINK or
Homozygosity mapper [20,22].
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Genes 2018, 9, 21 5 of 16
2.4. Data Sharing
Each ERDC partner shared candidate genes in biannual meetings. Thereafter, the corresponding
genes were screened for the presence of variants in WES data and homozygosity mapping data were
assessed for homozygous regions larger than 4 Mb containing these candidate genes. In addition,
candidate genes were posted at the open access ERDC website to increase the probability of finding
additional cases carrying variants in the same candidate genes [13].
3. Results
We performed an assessment to predict the pathogenicity of selected candidate variants by
combining: (a) minor allele frequency (ExAC); (b) in silico prediction program (CADD score); (c)
whether there is any interaction with retinal-associated protein (from previous studies or STRING
protein network database) [27]; and, (d) whether there is any described association with IRDs.
Subsequently, the total score was used to consider the likelihood of variants to be causative. In addition,
we also implemented the American College of Medical Genetics (ACMG) guidelines to predict variants
based on their pathogenicity [28]. Upon this assessment, variants in the known IRD-associated
gene SNRNP200 is the highest ranked classification ‘score 4’. For the other genes, two genes have
a ‘score 3’ using our assessment, i.e., DEAH-Box Helicase 32 (DHX32) and Zinc Finger Protein 513
(ZNF513). The eight remaining genes have a lower pathogenicity scoring with ‘score 2’ or low
pathogenicity scoring of ‘score 1’. Hence, these genes are better candidate in comparison to the other
genes. In addition, we provide the amino acid conservation for all the missense variants identified in
this study (Figure 3). Clinical details of affected individuals of all families are described in Table 2.
3.1. Score 4 Candidate IRD Gene
In the consanguineous Pakistani family G, we performed microarray SNP analysis prior to WES.
In the largest homozygous region (14.6 Mb), we identified a homozygous c.3269G>A (p.(Arg1090Gln))
variant in SNRNP200. This variant occurs in 3 of 121,400 (0.000025) alleles in ExAC and is absent in 180
ethnically matched in-house controls. The substitution affects a highly conserved amino acid and has
a PhyloP score [29] of 5.77 (range-14.1; 6.4). The new residue has a small physicochemical difference in
comparison to the wild type amino acid, with a Grantham [30] score of 43 (range 0–215). The wild type
arginine residue in position 1090 is located in the ratchet helix of the helical bundle (HB) of human Bad
Response to Refrigeration 2 (hBRR2) that forms a unidirectional tunnel for RNA molecules to promote
RNA unwinding events (Figure 4A,B). Arg1090 seems to be in direct contact with the RNA molecule
and an alteration in this position may disrupt the unwinding of hBRR2.
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Table 1. Assessment of sequence variants identified in this study.
Gene Mode of DNA Protein CADD_ ExAC $ Described Known Interpretation According to ACMG Guidelines #
Name Inheritance Zygosity Variant Variant Phred AC/AN/HA/AF ProteinInteraction
IRD-Associated
Gene Score * Type of Evidence Classification
SNRNP200 AR Hom c.3269G>A p.(Arg1090Gln) 29.6 3/121,400/0/0.00002471 PRPF4; PRPF6;PRPF8 [27] yes 4
PM1, PM5, PP1, PP2, PP3,
PP4 LP
DHX32 AR Hom c.2176del p.(Glu726Asnfs*57) NA 2/121,276/0/0.00001649 FAM161A [31] no 3 PVS1, PM4 P
ZNF513 AD Het c.724C>T p.(Arg242Cys) 17.61 0/121,412/0/0 OPN1SW;PDE6A [27] yes 3 PP2, PM2 US
DSCAML1 AR Hom c.925G>A p.(Ala309Thr) 34 2/91,000/0/0.00002198 no 2 PP3 P
EP300 AD Het c.1069G>A p.(Ala357Thr) 36 0/121,412/0/0 no 2 PP1, PP3, PM2 US
FDFT1 AR Hom c.930C>G p.(Phe310Leu) 19.38 0/121,412/0/0 no 2 PP1, PP3, PM2 US
NDRG4 AR Hom c.769T>C p.(Tyr257His) 27.4 0/121,412/0/0 no 2 PP1, PP3, PM2 US
OTOGL AR Het c.2318C>T p.(Pro773Leu) 27.6 89/118,882/2/0.0007486 no 2 PM3, PP3, BS2 US
OTOGL AR Het c.2833C>T p.(Arg945*) NA 9/118,122/0/0.00007619 no 2 PVS1, PM3 P
SYTL4 XL Hem c.164G>T p.(Ser55Ile) 26 0/121,412/0/0 RAB8A;RAB27A [32] no 2 PP3, PM2 US
TMED7 AR Hom c.418C>T p.(Arg140*) 37 0/121,412/0/0 no 2 PP1, PP3, PVS1, PM2 P
GPR45 AR Hom c.4G>A p.(Ala2Thr) 13.47 0/121,412/0/0 no 1 PP1, PM2 US
*: Pathogenicity scoring based on four parameters: (a) In silico prediction; (b) Minor allele frequency; (c) Known interaction with retinal-associated protein; (d) Whether association
with Inherited Retinal Disease (IRD) is known or not; Interpretation according to the American College of Medical Genetics (ACMG) guidelines #: Variant classification based on the
ACMG guidelines; ExAC $: Variant absent from Exome Aggregation Consortium (ExAC) were indicated as zero alleles from total of 121,412 alleles included in ExAC; AC: Allele count;
AD: autosomal dominant; AF: allele frequency; AN: allele number; AR: autosomal recessive; B: benign; BS: benign strong; HA: number of homozygous alleles; Hem: hemizygous; Het:
heterozygous; Hom: homozygous; LP: likely pathogenic; NA: not analyzed; PM: pathogenic moderate; P: pathogenic; PP: pathogenic supporting; PS: pathogenic strong; PVS: pathogenic
very strong; US: uncertain significance; XL: X-Linked.
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Table 2. Clinical details of patients with mutations in candidate genes identified in this study.
ID/Gender
/Origin
Age at
Diagnosis/Age
Recent
Examination
(yrs)
History
Visual
Acuity
(LogMAR)
RE/LE
Refraction Ophthalmoscopy Full FieldElectroretinogram
Goldmann
Perimetry
Optical
Coherence
Tomography
Fundus Autofluorescence Other Symptoms
A-II:1, ♂
Ghana 42/58
Impaired visual
acuity and night
blindness in 5th
decade
CF/CF
RE:S−1.00
C1.25 × 88◦/
LE: S−1.25
C1.00 × 89◦
Pale optic disks, mild
attenuated retinal
vessels, extensive
atrophy of the RPE in
the macula and
midperiphery with
hyperpigmentations,
peripheral RPE spared
NA Constricted upto 5◦
Atrophy of the
outer segments NA
Lens sclerosis,
Alpha-thalassemia
B-II:1, ♀
The
Netherlands
38/69
Night blindness
in 3rd decade
and visual field
loss in the 4th
decade
0.15/0.7
RE: S−1.75
C1.25 × 10◦/
LE: S+0.50
C1.25 × 0◦
Pale optic disks,
severely attenuated
retinal vessels, RPE
alterations in the
posterior pole,
midperipheral RPE
atrophy and peripheral
bonespicule-like
pigmentations
Photopic: severely
reduced response,
Scotopic: no reponse
Constricted up
to 10◦
Central and
peripheral
atrophy of the
outer segments,
intraretinal cysts
Hyper-autofluorescent
macula with
hypo-autofluorescent
perifoveal ring and
hypo-autofluoresent,
patchy dots
Pseudophakia. RE
traumatic corneal
perforation and
partial aniridia
C-II:2, ♀
Pakistan 20-30/45
Adult onset
nyctalopia and
reduced vision,
followed by loss
of acuity
0.2/0.3 Emmetropic
White dots and
intra-retinal pigment
migration in
mid-peripheral retina,
especially above and
below the optic disc.
Bulls eye maculopathy
Rod-cone dysfunction
confrontation
approximately
10◦
Outer retinal
degeneration,
relative sparing of
fovea
Concentric rings of hypo-
and hyper-autofluoresence
in the macula, consistent
with a bulls eye
maculopathy, and areas of
hypo-autofluorescence in
the mid-periperal retina
-
D-II:1, ♀
Muslim
Arab
Congenital/37
Congenital
photophobia
and reduced
visual acuity,
congenital
nystagmus
0.1/CF 1m NA NA
Photopic: severely
reduced responses,
Scotopic: slightly
reduced responses
NA NA NA -
D-II:2, ♀
Muslim
Arab
Congenital/25
Congenital
photophobia
and reduced
visual acuity,
congenital
nystagmus
CF 2m/CF
2m NA NA
Photopic: severely
reduced responses,
Scotopic: slightly
reduced responses
NA NA NA -
E-II:3, ♀
Turkey
early
infancy/4
Pendular
nystagmus,
reduced vision
1/4 APK/
1/3 APK
RE: S+4.75
C−2.50 ×
2◦/LE: S+5.0
C−2.5 × 4◦
no visible abnormalities
Photopic: reduced
responses, Scotopic:
NA
NA NA NA -
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Table 2. Cont.
ID/Gender
/Origin
Age at
Diagnosis/Age
Recent
Examination
(yrs)
History
Visual
Acuity
(LogMAR)
RE/LE
Refraction Ophthalmoscopy Full FieldElectroretinogram
Goldmann
Perimetry
Optical
Coherence
Tomography
Fundus Autofluorescence Other Symptoms
F-II:2, ♂
Algeria 2/22
Night blindness
at 2 yrs, at 12 yrs
minimal
peripheral
visual field,
moderate
photophobia
1.0/1.0
RE: S−0.50
C−0.50 ×
55◦)/LE:
C−1.00 × 100◦)
Depigmented
peripheral retina with
bone spicule
pigmentary deposits in
mid periphery. Macular
reflex is normal.
Narrowed retinal
vessels and pale optic
discs
LE: interpapillomacular
region is depigmented.
NA
Visual field is
tubular, with the
peripheral
isopter V4e
shortened at
15-20◦ around
fixative point
CME with foveal
thickness of 280
µm RE and 220
µm LE. Outer
retinal layers are
absent outside the
fovea
Typical
hypoautofluorescent spots
in mid periphery towards
the macula. A narrowed
ring of
hyperautofluorescence
around the fovea. LE:
hypoautofluorescent spots
superonasal of the macula
-
G-III:4, ♂
Pakistan
early
infancy/15
Night blindness
and visual field
loss
1.0/1.0 NA
Attenuated retinal
vessels, peripheral bone
spicule pigmentation
NA NA NA NA -
H-II:1, ♂
The
Netherlands
16/37
Impaired visual
acuity and
visual field loss
in the 2nd
decade
NLP/HM
3m
RE: NA / LE:
S−3.00
C1.75 × 177◦
RE: phthisis bulbi, LE:
Pale optic disk,
attenuated retinal
vessels, small island
with remaining RPE in
the macula, extensive
atrophy and bone
spicule pigmentations
in the periphery
Photopic: moderately
reduced response,
Scotopic: severely
reduced responses
LE: Peripheral
island inferior
Disorganization
and extensive
atrophy of the
outer retinal
layers and
thickened RPE in
the fovea
NA
RE: Traumatic
retinal
detachments,
aphakia.
Proliferative
vitreoretinopathy
I-IV:2, ♀
Asia
1st
decade/10
Reduced visual
acuity,
nystagmus
0.1/0.1 NA Bull’s eye maculopathy NA NA NA NA
Developmental
delay, tonic clonic
seizures
I-V:1, ♂
Asia
1st
decade/12
Reduced visual
acuity,
nystagmus
0.2/0.3 NA Bull’s eye maculopathy NA NA NA NA
Developmental
delay, tonic clonic
seizures
J-IV:3, ♂
France 5-20/63
Night blindness
and visual field
loss
LP to 1.0/
LP to 1.0 Variable Pigment deposits
No or reduced
responses
Slightly
decreased V4e
isopter in
periphery to
tubular visual
field
Moderate
decrease of the
outer nuclear
layer in periphery
to complete
absence of outer
nuclear layer
Typical
hypoautofluorescence spots
in retinal periphery
-
K-IV:1, ♀
The
Netherlands
41/53
Impaired visual
acuity, and night
blindness in the
5th decade
0.7/0.6
RE: S+2.50
C0.75 × 172◦
/LE: S+3.00
C1.50 × 165◦
Mild pallor of the optic
disk, mild attenuated
retinal vessels, cystoid
maculopathy, thinning
of the RPE in the
periphery with
intraretinal bone
spicule pigmentations
(LE > RE)
Photopic: severely
reduced responses,
Scotopic: severely
reduced responses
Peripheral
sensitivity loss,
no absolute
defects
CME, peripheral
atrophy of the
outer segments
Hypoautofluorescent flecks
in the fovea,
hyperautofluorescent ring
along the macula
superimposed to the
underlying edema, coarse
hypoautofluorescent spots
along the vascular arcades
Cystoid
maculopathy,
refractory to
systemic
treatment with
Diamox® and
Octreotide®
APK: Amsterdam Picture Chart; BE: Both eyes; C: Cylindrical, CF: Counting fingers; CME: Cystoid macular edema; HM: Hand movement; LE: Left eye; LP: Light perception; NA: Not
analyzed; NLP: Near light perception; m: Months; RE: Right eye; RP: Retinitis pigmentosa; S: Sphere, ♀: Female; ♂: Male.
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Figure 3. Amino acid conservation for the missense variants identified in this study.  
DSCAML1: DS Cell Adhesion Molecule Like 1; EP300: E1A Binding Protein P300; FDFT1: Farnesyl-
Diphosphate Farnesyltransferase 1; GPR45: G Protein-Coupled Receptor 45; NDRG4: NDRG Family 
Member 4; OTOGL: Otogelin Like; SNRNP200: Small Nuclear Ribonucleoprotein U5 Subunit 200; 
SYTL4: Synaptotagmin Like 4; ZNF513: Zinc Finger Protein 513. 
 
Figure 4. 3D protein structure modeling for missense variants in SNRNP200 due to autosomal 
dominant and recessive variants. (A) An overview of the 3D protein structure model for SNRNP200. 
Arg1090 is located in the center of the model indicated by the square. (B) Modeling of the missense 
variant identified in family G. The autosomal recessive variant alters to glutamine that is uncharged 
but has the same polarity as the wild type amino acid. (C) The previously described SNRNP200 
variant p.(Arg1090Gln) leads to a dominantly inherited retinitis pigmentosa (RP). The wild type 
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Figure 3. Amino acid conservation for the missense variants identified in this study. DSCAML1: DS
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SYTL4: Synaptotagmin Like 4; ZNF513: Zinc Finger Protein 513.
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Figure 4. 3D protein structure modeling for missense variants in SNRNP200 due to autosomal dominant
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p.(Arg1090Gln) ads t a dominantly inherited retinitis pigmentosa (RP). The wild type arginine is
altered to a nonpolar and hydrophobic leucine.
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3.2. Score 3 Candidate IRD Genes
The DHX32 extension variant c.2176del (p.(Glu726Asnfs*57)) in family A will result in a frameshift
with read-through of the stop codon resulting in a transcript encoding 57 additional amino acids when
compared to the wild type protein. This variant has a minor allele frequency of 0.000016 in the ExAC
database. DHX32 is one of DEAD (Asp-Glu-Ala-Asp) box proteins with a putative role as a RNA
helicase that is involved in nuclear regulation and mitochondrial gene expression. As the variant occurs
in the last exon of DHX32 there will be no nonsense mediated decay. The addition of 57 amino acids
could however destabilize the protein’s folding or it might interfere in protein-protein interactions.
The third candidate gene is ZNF513. The variant c.724C>T (p.(Arg242Cys)) was identified in two
individuals from family K affected with late onset autosomal dominant RP. This variant is absent in the
ExAC database. The variant affects a highly conserved amino acid and substitutes a nucleotide with a
PhyloP score of 2.71. In addition, the wild type arginine residue has a large physicochemical difference
with cysteine, with a Grantham score of 180. Based on the family history (grandfather deceased at age
44 years when disease may not yet have appeared; great-grandfather mentioned to be blind) there is
strong supporting evidence for a dominant inheritance pattern. To further rule out autosomal recessive
inheritance, a detailed analysis of copy number variants was performed. In the fully covered gene,
there was no evidence for the presence of deletions or duplications in ZNF513 in the affected proband.
3.3. Score 2 Candidate IRD Genes
In family B, we identified a homozygous missense c.925G>A (p.(Ala309Thr)) variant in DSCAML1,
a gene that encodes the Down syndrome cell adhesion molecule-like 1 transmembrane protein.
The substitution occurs in the amino acid that is highly conserved. The variant affects a highly
conserved nucleotide with a PhyloP score of 5.86, but the altered amino acid is expected to have
a relatively small physicochemical difference with a Grantham score of 58. This variant is found
in 0.000022 of alleles in the ExAC database. All of the in silico prediction programs predicted this
substitution to be deleterious, supported by the high CADD score of 34. The variant is located in the
region that encodes the Immunoglobulin C2-type domain of the gene.
Down syndrome cell adhesion molecule (DSCAM) and DSCAML1 are known to be cell
adhesion molecules that play roles in several neurodevelopmental functions, including neuronal
self-avoidance [33]. This adhesion molecule is expressed in a subset of amacrine cells and most retinal
ganglion cells (RGCs) soon after they develop and promotes laminar specificity in the retinal synaptic
connections via homophilic intracellular interactions [33]. A recent study in mice shows the expression
of Dscaml1 in the rod circuit, and the lack of Dscaml1 leads to fasciculate rod bipolar cell dendrites and
clumped amacrine cell bodies, suggesting its role in the neuronal self-avoidance. Moreover, this study
also suggested the importance of Dscaml1 for rod bipolar cell dendrite organization and amacrine cell
mosaic patterning [34].
Segregating compound heterozygous variants c.2318C>T and c.2833C>T (p.(Pro773Leu) and
p.(Arg945*)) were identified in Otogelin Like (OTOGL) in family F with non-syndromic autosomal
recessive RP. The missense variant alters a highly conserved nucleotide and amino acid (proline),
with a conserved nucleotide with PhyloP score of 4.00. This variant occurs in 89/118,882 alleles
(0.00075) in the ExAC database, i.e., heterozygously in 85 persons and homozygously in two persons.
The allele frequency of the nonsense variant was 0.000076 in the ExAC database and predicted to
result in nonsense mediated decay. If there would be a shortened protein, it will no longer include two
von Willebrandt factor, type D domains, two C8-domains, and the C-terminal domain. Pathogenic
mutations in OTOGL are associated with sensorineural hearing loss [35,36]. Based on their allele
frequencies, we considered both variant to be less likely associated with the disease phenotype;
however, no other outstanding variants were observed. Homozygosity mapping with the 250.000
SNP array had indicated two homozygous regions in which no currently known IRD-associated
genes appear.
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In the four-generation family J, we detected a heterozygous missense c.1069G>A (p.(Ala357Thr))
variant in the E1A Binding Protein P300 (EP300) gene that inherited in an autosomal dominant manner.
The variant alters a moderately conserved amino acid and affects a highly conserved nucleotide
(PhyloP: 6.34). This substitution is absent from the ExAC database and all in silico predictions show
this variant to be pathogenic. It occurs in exon 4 that encodes the transcription adaptor putative
Zinc finger domain of the EP300 protein. The EP300 gene encodes p300 histone acetyltransferase
that modulate transcription through chromatin remodeling and also plays role in cell proliferation
and differentiation [37]. EP300 is ubiquitously expressed in adult tissue. Heterozygous truncating
variants in this gene have previously been associated with the Rubinstein-Taybi syndrome, a condition
that is characterized by short stature, intellectual disability, facial dysmorphology, and often retinal
disorders [38]. The non-ocular features of Rubinstein-Taybi syndrome were not observed in the
proband. A study using conditional KO Ep300 mice in differentiating rods or cones using opsin driven
Cre-recombinase showed that p300 is required for photoreceptor-specific chromatin organization,
function, gene expression, and to maintain cell identity [39]. In addition, a recent study in zebrafish
light-induced larvae suggested the role of EP300 in protecting photoreceptor cells from light-induced
damage and shows that EP300 activation as a potential approach for the treating retinal degenerative
diseases [40]. Taken together, this evidence suggests that EP300 is as plausible candidate gene that
is associated with retinal phenotype in this family. Loss of function may lead to a severe phenotype,
while missense variant in this family may still retain all the essential domain of p300, thus only causes
retinal phenotype.
Homozygosity mapping in combination with WES analysis detected a homozygous missense
c.930C>G (p.(Phe310Leu) variant in Farnesyl-Diphosphate Farnesyltransferase 1 (FDFT1) in two
siblings from family C with rod-cone dystrophy. FDFT1 resides in the single homozygous region shared
by the two affected siblings spanning 11.6 Mb. The variant affects a highly conserved phenylalanine,
and a poorly conserved nucleotide (PhyloP: 1.09). The mutant leucine is also present in Baker’s yeast
(Supplemental Figure S1). This substitution occurs in 87 out of 121,400 alleles (0.00072). The FDFT1
gene encodes farnesyl-diphosphate farnesyltransferase 1 enzyme, which catalyzes the dimerization of
farnesyl-diphosphate to form squalene in the mevalonate pathway. Two IRD-associated genes have
previously been linked to the process of prenylation [41]. The mevalonate kinase (MVK) gene has been
implicated in non-syndromic RP [42], and mutations in Member RAS Oncogene Family 28 (RAB28),
encoding a prenylated RAB28 protein, are a cause of CRD [17]. Despite this ‘guilt by association’, the
information provided above suggest this variant to be benign.
In family E with achromatopsia, we identified a homozygous c.769C>T (p.(Tyr257His))
substitution in the NDRG Family Member 4 (NDRG4) gene. This gene resides in the largest overlapping
homozygous region of 76.5 Mb shared by the two affected siblings, but not by the healthy sibling. This
highly conserved nucleotide variant (PhyloP: 4.48) is absent in the ExAC database and alters a highly
conserved tyrosine. The variant is predicted to be damaging by all prediction programs and occurs in
the Ndr domain of the NDRG4. The gene is expressed in the retina based on the ocular tissue database,
human proteome map, Gepis tissue and human retinal transcriptome. No association or interaction
with retinal-associated protein is known for this protein. When compared to the missense variant
identified in this study, the Ndrg4-deficient mice present with impaired spatial learning and memory,
but normal motor function [43]. Previous studies have shown that Ndrg4 mRNA is expressed in the
amacrine cells, horizontal cells, and ganglion cells in the developing mouse retina, and amacrine and
possibly ganglion cells at 96 hours post fertilization in zebrafish [44].
A hemizygous c.164G>T (p.(Ser55Ile)) variant in Synaptotagmin Like 4 (SYTL4) was found in
family H, which was not present in the ExAC database. No other family members were available to
investigate the X-linked mode of inheritance. The substitution alters an evolutionary highly conserved
serine, and also affects a highly conserved nucleotide with a PhyloP score of 5.21. The variant occurs
in exon 4, which encodes the Rab binding domain. All the in silico tools suggest that the variant
damages the protein. The larger size and the altered hydrophobicity of the new residue may disrupt
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the forming of the hydrogen bond between serine at position 55 with lysine at position 49 in the wild
type situation. The altered residue is located on the protein surface, and thus may affect interaction
with other molecules or protein domains. SYTL4 encodes a member of the synaptotagmin like protein
family, which contains the N-terminal Rab27 binding domain and C-terminal tandem C2 domain.
The encoded protein binds to Syntaxin Binding Protein 1 (STXBP1), Member RAS Oncogene Family
3A (RAB3A), Member RAS Oncogene Family 8A (RAB8A) and Member RAS Oncogene Family 27B
(RAB27B), and interacts with Myosin VA (MYO5A).
In family I, we identified a homozygous nonsense c.418C>T (p.(Arg140*)) variant in
Transmembrane P24 Trafficking Protein 7 (TMED7). This variant is absent from the ExAC database.
TMED7 might play an important role in vesicular protein trafficking. This variant will result in either
a truncated protein product lacking the EMP24_GP25L or GOLD domain, or may be subjected to
nonsense mediated decay.
Thus far, no disorder has been associated with mutations in this gene. Individuals carrying
this variant demonstrated an early onset visual impairment in the first decade of life. In addition,
nystagmus, developmental delay and tonic clonic seizures also occurred in the patient.
3.4. Score 1 Candidate Gene
We identified a homozygous missense variant c.4G>A (p.(Ala2Thr)) in G Protein-Coupled
Receptor 45 (GPR45). This variant occurs in a homozygous state in two affected sisters with CRD
in a consanguineous Israeli Muslim Arab family D. The variant is predicted to result in a small
physicochemical change with a Grantham score of 58; the mutant threonine is larger than alanine,
which may destabilize GPR45. The variant affects a moderately conserved nucleotide with a PhyloP
score of 1.90 and the alanine at position 2 is moderately conserved up to frog. This variant is not
present in the ExAC database and all in silico tools predict the variant to be deleterious. In addition,
the variant resides outside the region that encodes functional protein domain. GPR45 is a member of
the G protein-coupled receptor (GPCR) superfamily that is known to modulate physiological processes
in the neurological systems [45].
4. Discussion
Whole exome sequencing has been instrumental for IRD gene discoveries since 2011 [15,46,47].
The implementation of this technology has contributed to the identification of ~40 novel genes that
are associated with syndromic and non-syndromic IRDs in the last six years. Furthermore, novel
genotype-phenotype correlations were identified for several IRD-associated genes by using exome
sequencing. A tendency can be observed, as the early-discovered genes are more frequently mutated
than the more recently identified genes. Previous genetic studies employing homozygosity mapping
and WES in the Saudi Arabian population shows a small proportion of IRD cases (3–4%) that carry
a mutation in novel IRD-associated genes [8,9]. Additionally, a gene panel study in 537 IRD cases
demonstrated 79% of diagnostic yield in the genes that were discovered between 1995 and 2004 [48].
Together with challenges in interpreting novel variants, this low mutational load phenomenon led
to the identification of many variants in novel candidate genes in singleton cases without any clear
functional consequences.
The ERDC aims to identify the remaining unidentified IRD-associated genes by data sharing.
In the past few years, the ERDC was able to identify several genes associated with IRDs [14–16,49].
To enable discovery of additional families harboring overlapping pathogenic variants the online
Web-tool GeneMatcher may also be utilized [50]. This tool allows for researchers and clinicians to
upload a gene with information about the identified genetic variants and the phenotype found in the
patient that carries this variant or combination of variants.
Upon screening of WES and identity-by-descent data, 11 genes remained as candidates that occur
in single families or cases. Using our pathogenicity assessment SNRNP200, DHX32, and ZNF513
are the top ranked candidate genes based on the allele frequency, in silico prediction and interaction
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with the known IRD genes. Screening of IBD and WES data of unsolved IRD cases did not yield
additional cases. The lower ranked candidate genes have generally weaker pathogenicity prediction
scores, however all stand out when compared to other variants seen in the corresponding patients.
Besides the identification of novel candidate genes, we also revealed a novel mode of inheritance in
two previously described IRD-associated genes. The SNRNP200 variant is located in the Sec63 domain
and predicted to be deleterious. Interestingly, an overlapping variant in this position, c.3269G>T
(p.(Arg1090Leu), Figure 4C), has been previously identified in a large Chinese family segregating an
autosomal dominant form of RP. SNRNP200 encodes BRR2, a member of the spliceosome complex.
Functional assays in yeast using a Brr2p construct containing p.(Arg1090Leu) demonstrated a splice
defect, suggesting the association of SNRNP200 with the disease phenotype. In the autosomal dominant
RP associated variant, the wild type arginine is altered to a nonpolar and hydrophobic leucine.
On the other hand, the autosomal recessive RP-associated variant alters to glutamine that is uncharged
but has the same polarity as the wild type amino acid. The comparison of the two new residues
in the 3D structure of SNRNP200 shows that the alteration to leucine shows a greater structural
difference in comparison to glutamine. We hypothesize that p.(Arg1090Gln) only causes disease in
a homozygous state, as its effect on the SNRNP200 activity is approximately half of the effect of
p.(Arg1090Leu). The causality of autosomal recessive variants in SNRNP200 was suggested by Wang
et al. In a Chinese Leber congenital amaurosis patient who carried a homozygous p.(Pro1045Thr)
variant [51]. Moreover, Bujakowska and colleagues proposed autosomal recessive inheritance in a
RP patient with compound heterozygous variants in SNRNP200 consisting of the same hypomorphic
missense variant p.(Pro1045Thr) and a 1.1-Mb deletion spanning SNRNP200 [52].
The ZNF513 mutant residue Cys242 is predicted to have a larger size than the normal Arg242,
which may destabilize the protein structure. The hydrophobicity of the wild type and mutant
residue differs. Hydrophobic interactions, either in the core of the protein or on the surface, will
be lost. The homozygous c.1015T>C (p.(Cys339Arg)) variant that was previously associated with
autosomal recessive RP in a consanguineous family from Pakistan [53] is present three times in a
homozygous state in ~60,000 ‘healthy’ individuals in ExAC, which sheds doubt on its pathogenic
character. Knockdown of znf513 in zebrafish model however suggested its role in retinal development
and photoreceptor maintenance, as shown by the eye dysmorphology and photoreceptors loss in the
knockdown model [53]. Possibly, the p.(Cys339Arg) variant shows reduced penetrance or is associated
with variable age of onset of disease.
Among the score 2 classified genes, we identified a homozygous truncating variant in TMED7.
The role of TMED7 in protein trafficking and lack of an associated disease marks TMED7 as a putative
target for further investigation. Similar to the other candidate genes, additional cases with variants in
this gene would support its involvement in IRD.
In conclusion, we have identified 11 candidate IRD-associated genes through data sharing. To
prove that these candidate genes are true IRD causative genes, whole genome sequencing in these
cases could further confirm their candidacy by exclusion of other genetic causes. Moreover, additional
unrelated cases need to be identified and additional functional evidence can support causality. For
this, we encourage a worldwide genotype-phenotype data sharing in order to boost the completion of
the IRD genetic puzzle.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/9/1/21/s1. Table S1:
Provided details on whole exome sequencing and linkage/homozygosity approach. Figure S1: Amino acid
conservation for the missense variants identified in FDFT1 in Human and Baker’s yeast.
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